Dan Nomura

• B.A. University of California, Berkeley (2003) in Molecular and Cell Biology
• Ph.D. University of California, Berkeley (2008) in Molecular Toxicology
• Postdoctoral Fellow at The Scripps Research Institute (2011) in Chemical Biology
• Assistant Professor, University of California, Berkeley (2011-2015)
• Searle Scholar (2012)
• ACS Research Scholar Award (2014)
• Associate Professor, University of California, Berkeley (2015-2019)
• Director, Novartis-Berkeley Translational Chemical Biology Institute (2017-current)
• Co-Founder for Frontier Medicines (2018-current)
• The Mark Foundation for Cancer Research ASPIRE award (2019)
• Professor, University of California, Berkeley (2019-current)
• National Cancer Institute Outstanding Investigator Award (2022)
• Investment Advisory Board Member at Droia Ventures (2022-current)
• Investment Advisory Partner at a16z (2023-current)
• iPartner at The Column Group (2023-current)
• Co-Founder for Zenith (2024-current)
• Co-Director, UC Berkeley Molecular Therapeutics Initiative (2024)

Dan Nomura is a Professor of Chemical Biology and Molecular Therapeutics in the Department of Chemistry and the Department of Molecular and Cell Biology in the Division of Molecular Therapeutics at the University of California, Berkeley and an Investigator at the Innovative Genomics Institute. He is also the Co-Director of the Molecular Therapeutics Initiative at UC Berkeley. He is an Adjunct Professor in the Department of Pharmaceutical Chemistry at UCSF. Since 2017, he has been the Director of the Novartis-Berkeley Translational Chemical Biology Institute focused on using chemoproteomic platforms to tackle the undruggable proteome. He is Co-Founder of Frontier Medicines, a start-up company focused on using chemoproteomics and machine learning approaches to tackle the undruggable proteome. He is also the Founder of Vicinitas Therapeutics based on his group’s discovery of the Deubiquitinase Targeting Chimera (DUBTAC) platform for targeted protein stabilization. In addition, he is also a co-founder of Zenith. He is on the Scientific Advisory Boards for Frontier Medicines, Vicinitas Therapeutics, Zenith, Photys Therapeutics, Apertor Pharma, Oerth Bio, and Deciphera Pharmaceuticals. Nomura is also on the scientific advisory board of The Mark Foundation for Cancer Research. He is also an Investment Advisory Partner at a16z Bio+Health, an Investment Advisory Board member at Droia Ventures, and an iPartner with The Column Group. He earned his B.A. in Molecular and Cell Biology in 2003 and Ph.D. in Molecular Toxicology in 2008 at UC Berkeley with Professor John Casida and was a postdoctoral fellow at Scripps Research with Professor Benjamin F. Cravatt before returning to Berkeley as a faculty member in 2011. Among his honors include the National Cancer Institute Outstanding Investigator Award, Searle Scholar, and the Mark Foundation for Cancer Research ASPIRE award.